Detecting Infections Rapidly and Easily for Candidemia Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to validate clinical performance (i.e. estimated sensitivity and specificity) of the T2 Candida test on the T2 DX Instrument compared to blood culture results and/or known Candida positive status of prospectively collected and contrived (i.e. Candida-spiked) clinical specimens.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)

NCT01525095

Candidemia

COMPLETED

Serial Therapeutic and Antifungal Monitoring Protocol

NCT02163889

Candidemia

COMPLETED

Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility

NCT01077336

Blood Stream Infections Candida

COMPLETED

Evaluation of Rapid Diagnostic Device for the Detection of Candida Auris

NCT07253311

Candida Auris Infection Candida Auris Colonization Nosocomial Infections

NOT_YET_RECRUITING

The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis

NCT05235711

Fungal Infection Candidiasis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will prospectively collect and analyze whole blood T2 clinical research specimens and concomitant blood culture specimens from patients who have been referred for a blood culture per routine standard of care. Additional analysis of blinded, contrived (i.e. Candida spiked and un-spiked whole blood) specimens will be completed by study sites to augment the analysis of Candida positive blood specimens prospectively obtained from the study population.

The clinical performance of the T2 Candida test on the T2 Dx Instrument will be evaluated by calculating the:

* Estimated clinical specificity of the T2Candida test results compared to Candida negative blood culture results in prospectively collected specimens, and the
* Estimated sensitivity of the T2 Candida test results compared to the known Candida positive status or Candida positive blood culture status of contrived specimens that have been spiked at clinically relevant concentrations of the target organisms and, where detected, to Candida positive blood culture results in prospectively collected clinical specimens.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Candidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blood culture

Subjects have had a blood culture ordered, per routine standard of care

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject or subject's authorized representative must be able to understand, read and sign the study specific informed consent form after the nature of the study has been fully explained to them.
2. Subject has had a blood culture ordered, per routine standard of care.
3. Subject is between 18-95 years of age

Exclusion Criteria

1. Subject has other co-morbid condition(s) that, in the opinion of the Investigator, could limit the subject's ability to participate in the study or impact the scientific integrity of the study.
2. Subject has had previous specimens tested by the T2Candida assay with valid results.
3. Subject has had an anti-fungal drug administered through the same port or central line as is used to collect the clinical research specimens.
4. Treatment of subject with any novel drug compound within 30 days prior to the collection of T2 blood specimens.
5. T2 clinical specimen, Tube A contains \<3ml of blood.

Minimum Eligible Age

18 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No